Diffuse midline gliomas harboring a recurrent H3 lysine 27-to-methionine (p.Lys27Met, H3K27M) constitute a recently defined pathologic entity with a particularly poor prognosis. They mainly occur in midline structures, such as the pons and thalamus of children and young adults, and are highly infiltrative [2] . More recently, case reports have described the H3K27M mutation in circumscribed (non-diffuse) gliomas, many of which are low-grade (e.g., pilocytic astrocytoma, ganglioglioma) [1, [3] [4] [5] (additional references are provided in Online Resource 1). Because of the rarity of these tumors, it is unknown whether they carry the poor clinical outcome ascribed to H3K27M-mutant infiltrating gliomas of the midline. Here, we address this gap in our knowledge by performing an integrated meta-analysis on collated clinical and pathologic data from published studies, data repositories, and collaborative efforts.
A systematic search of the literature was performed from 2012 to November, 2017. Tumors were categorized based on diagnosis, location, histologic grade, growth pattern, and H3K27M mutation status. IDH 1/2-mutant diffuse gliomas were excluded to avoid bias arising from the good prognosis attributed to this mutation. Circumscribed gliomas included pilocytic astrocytoma, ganglioglioma/glioneuronal tumor/ ganglion cell tumor, pleomorphic xanthoastrocytoma, and ependymoma. Data from The Cancer Genome Atlas (TCGA) (http ://canc erge nome .nih.gov/) were obtained through the cBioPortal and PedcBioPortal for Cancer Genomics. Factors extracted included age, sex, overall survival, tumor location, histopathologic diagnosis, and WHO grade. Patient samples were then cross-referenced across studies to filter out duplicate data. Cases were also acquired from our inhouse sequencing efforts and through collaboration with the Mayo Clinic in Rochester, Minnesota. Co-occurring mutations were also documented. The endpoint extracted from all data sources was overall survival (OS). Survival functions were estimated using the Kaplan-Meier method and differences analyzed with the log-rank (Mantel-Cox) test using GraphPad Prism software (version 7). The Coxproportional hazards model was used to calculate hazard ratios (HR) using SPSS (version 24, IBM). All studies were approved by ethics committees at the respective institutions (see Online Resource 1 for further details of the methods).
Among published studies and through institutional collaboration, we identified 28 cases of H3K27M-mutant circumscribed gliomas (grade I: n = 19; grade III, n = 9). Histopathology included pilocytic astrocytoma (n = 7), ganglioglioma (n = 10), anaplastic ganglioglioma (n = 3), glioneuronal tumor (n = 1), anaplastic glioneuronal tumor (n = 1), ganglion cell tumor (n = 1; Fig. 1a-d) , anaplastic ependymoma (n = 3), and circumscribed glioma, not further specified (n = 2) (see Online Resource 2 for references and case details). Strikingly, more than 96% (n = 26/27 cases with location provided) of H3K27M-mutant circumscribed gliomas occurred within the midline, including the brainstem (n = 7), thalamus (n = 5), cerebellum (n = 2), spinal cord (n = 8), and other midline regions (peduncle, posterior fossa, and midline-not further specified; n = 4) (Fig. 1g) . Of the remaining two cases, one was reported in the cerebrum, while the location was not specified for the other. H3K27M mutations occurred in H3F3A (n = 21), HIST1H3B (n = 1), HIST1H3C (n = 1), and five cases were detected by immunohistochemistry. Information on co-occurring somatic mutations was available in 50% (14/28) of cases. The most frequent alteration was BRAF V600E (n = 7) mutations followed by ATRX (n = 3), FGFR1 N546K (n = 2), and NF1 (n = 2) (see Online Resource 2). Copy number alterations were reported in chromosomes 13 and 17 in two tumors.
Survival information was available for 21 cases (grade I: n = 14; grade III: n = 7). Univariate analysis of these tumors demonstrated poor OS compared to H3-wild-type circumscribed gliomas (n = 59; grade I: n = 51; grade III: n = 8) (log-rank, p < 0.0001), but a significantly improved OS compared to H3/IDH-wild-type (log-rank, p = 0.025) and H3K27M-mutant diffuse gliomas (log-rank, p < 0.0001) (Fig. 1e) . This association remained significant after matching tumors for grade (grade I, log-rank, p < 0.0001; Fig. 1f ) and treatment [chemotherapy and/or radiotherapy, log-rank, p < 0.0001; Supp. Fig. (Online Resource 3) ]. Cox regression analysis with age, sex, grade, and mutation status included as covariates showed the H3K27M mutation remained an independent predictor of OS (HR, 5.980; 95% CI, 1.839-19.445; p = 0.003; Fig. 1h ). These results confirm that the poor prognosis of the H3K27M mutation also extends to circumscribed gliomas. While H3K27M-mutant circumscribed gliomas show poor survival compared to H3-wild-type circumscribed gliomas, prognosis remains significantly better than both H3K27M-mutant and H3-wild-type diffuse gliomas. This has important implications regarding the current WHO grading of H3K27M-mutant diffuse gliomas, which are uniformly labeled as grade IV. However, we note that an important limitation to our study is the relatively short follow-up duration, largely owing to the rarity of these tumors. We also show that H3K27M-mutant circumscribed gliomas show a similar predilection for midline regions. Our data suggest that midline circumscribed gliomas should be routinely tested for H3K27M mutations.
